166 related articles for article (PubMed ID: 21618420)
1. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology.
van Litsenburg RR; Uyl-de Groot CA; Raat H; Kaspers GJ; Gemke RJ
Pediatr Blood Cancer; 2011 Dec; 57(6):1005-10. PubMed ID: 21618420
[TBL] [Abstract][Full Text] [Related]
2. The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China.
Luo XQ; Ke ZY; Guan XQ; Zhang YC; Huang LB; Zhu J
Pediatr Blood Cancer; 2008 Aug; 51(2):204-9. PubMed ID: 18454471
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
[TBL] [Abstract][Full Text] [Related]
5. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
6. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
7. [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
Kwiecińska K; Balwierz W; Moryl-Bujakowska A; Wachowiak J; Derwich K; Matysiak M; Pawelec K; Chybicka A; Dobaczewski G; Kowalczyk JR; Wiśniewska-Slusarz H; Sońta-Jakimczyk D; Szczepański T; Tomaszewska R; Wysocki M; Styczyński J; Balcerska A; Płoszyńska A
Przegl Lek; 2010; 67(6):350-4. PubMed ID: 21344760
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia.
Welch HG; Larson EB
N Engl J Med; 1989 Sep; 321(12):807-12. PubMed ID: 2505077
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
10. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
12. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
13. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
14. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
15. [Childhood acute lymphoblastic leukemia in Norway 1992-2000].
Kolmannskog S; Flaegstad T; Helgestad J; Hellebostad M; Zeller B; Glomstein A
Tidsskr Nor Laegeforen; 2007 May; 127(11):1493-5. PubMed ID: 17551551
[TBL] [Abstract][Full Text] [Related]
16. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
17. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
18. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
Yamaji K; Okamoto T; Yokota S; Watanabe A; Horikoshi Y; Asami K; Kikuta A; Hyakuna N; Saikawa Y; Ueyama J; Watanabe T; Okada M; Taga T; Kanegane H; Kogawa K; Chin M; Iwai A; Matsushita T; Shimomura Y; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2010 Dec; 55(7):1287-95. PubMed ID: 20535816
[TBL] [Abstract][Full Text] [Related]
20. Curing children with leukemia in West Virginia.
Ritchey AK; Starling KA; Keller FG; Martin J; Steiner ME; Defazio J
W V Med J; 1997; 93(4):179-81. PubMed ID: 9274141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]